Red Clover Botanical Dietary Supplements - Metabolism and Safety in Women
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Area Under the Curve (AUC)
Study Overview
Brief Summary
Human safety studies were carried out to test whether red clover botanical dietary supplements used by peri- and post-menopausal women are safe to use with Food and Drug Administration (FDA)-approved drugs. To test this, a red clover dietary supplement (previously tested in women at the University of Illinois at Chicago without any harmful effects) was given with four selected FDA-approved drugs to determine if the red clover supplement can increase or decrease how these medications are absorbed, metabolized and excreted by the human body. Preclinical studies predicted that the red clover supplement might affect the metabolism or break down of these probe drugs.
Detailed Description
At the start of a study, subjects were administered low doses of a mixture of four FDA-approved drugs (caffeine, tolbutamide, dextromethorphan, and alprazolam), and serial blood samples were drawn and analyzed for the concentration of each drug over time. Afterwards, participants took the red clover dietary supplement twice orally daily for 14 days to allow for potential inhibition or induction of drug metabolizing enzymes and transporters. Thereafter, the same drugs were taken again to obtain a second measure of drug concentrations in blood over time. Changes in the concentration-time curve values for each probe drug obtained before and after ingestion of the supplement were evaluated to determine if metabolism of the probe drugs was impacted by the red clover dietary supplement.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Other
- Masking
- None
Eligibility Criteria
- Ages
- 40 Years to 79 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •healthy peri- and post-menopausal women ages 40 - 79
- •non-smokers
- •no-significant medical conditions as assessed by subject-reported medical history, physical examination and blood and urine chemistry screens
- •no medical condition that requires chronic use of medication
Exclusion Criteria
- •known allergies or hypersensitivity to caffeine, dextromethorphan, sulfonylureas (tolbutamide), benzodiazepines, or red clover
- •positive pregnancy test
- •use of hormone therapy within 8 weeks of study initiation for oral agents, 4 weeks for transdermal or other topical agents
- •use of caffeine products 7 days before study participation or during the study
- •use of citrus products 7 days before study participation or during the study
- •other prescription (with the exception of the Mirena® IUD) or non-prescription medicines within the 2 weeks prior to study initiation or during the study
- •chronic diseases, such as inflammatory bowel disease, that could alter the absorption or metabolism of the probe substrates
- •unwillingness to comply with study requirements
- •current participation in another clinical trial
- •CYP2D6 deficiency based on phenotyping at screening
- •red clover or soy intake (whether as a botanical dietary supplement, food, drink or otherwise) within the previous two weeks and during the study
- •use of any dietary supplements within the last 2 weeks prior to study initiation and during the study
- •extreme obesity (defined as >40 BMI)
- •alcohol or drug abuse
- •chronic diseases such as diabetes.
Arms & Interventions
Trifolium pratense
Red clover extract; 2 gelatin capsules (398 mg extract) per day for 14 days
Intervention: Trifolium pratense (Dietary Supplement)
Outcomes
Primary Outcomes
Area Under the Curve (AUC)
Time Frame: baseline and 14 days
Concentrations of probe drugs from blood draws at the conclusion of the 14-day intervention were used to calculate areas under the (extrapolated) concentration-time curve to determine any changes compared to pre-intervention.
Secondary Outcomes
- Peak Concentration(baseline and 14 days)
- Apparent Clearance(baseline and 14 days)
- Time for Peak Concentration(baseline and 14 days)
- Drug Half-life(baseline and 14 days)
Investigators
Elena Barengolts
Principle Investigator
University of Illinois at Chicago